Adjunctive herbal medicine with carbamazepine
for bipolar disorders: A double-blind, randomized, placebo-controlled study

doi:10.1016/j.jpsychires.2005.06.002
Copyright © 2005 Elsevier Ltd All rights reserved.
Adjunctive herbal medicine with carbamazepine for bipolar disorders:
A double-blind, randomized, placebo-controlled study
Zhang-Jin Zhanga,
,
,
Wan-Hu Kanga,
Qing-Rong Tanb,
Qiang Lia,
Cheng-Ge Gaoa,
Feng-Gang Zhangb,
Huai-Hai Wangb,
Xian-Cang Maa,
Ce Chena,
Wei Wanga,
Li Guob,
Ya-Hong Zhangb,
Xiao-Bo Yanga
and Guang-De Yangc
aDepartment of Psychiatry, The First Hospital, Xi’an Jiaotong
University College of Medicine, Xi’an, Shannxi 710061, China
bDepartment of Psychiatry, Xijing Hospital, The Fourth Military
Medical University, Xi’an, Shannxi 710032, China
cResearch and Engineering Center for Natural Medicine, Xi’an
Jiaotong University, Xi’an, Shaanxi 710061, China
Received 11 March 2005; revised 6 June 2005; accepted 17 June
2005. Available online 2 August 2005.
AbstractChinese herbal medicines possess the
therapeutic potential for mood disorders. This double-blind, randomized,
placebo-controlled study was designed to evaluate the efficacy and side
effects of the herbal medicine called Free and Easy Wanderer Plus (FEWP)
as an adjunct to carbamazepine (CBZ) in patients with bipolar disorders.
One hundred and twenty-four bipolar depressed and 111 manic patients were
randomized to treatment with CBZ alone, CBZ plus FEWP, or equivalent placebo
for 12 weeks. CBZ was initiated at 300 mg/day and FEWP was given at a
fixed dose of 36 g/day. Efficacy measures included the Hamilton Rating
Scale for Depression, Montgomery-Asberg Depression Rating Scale , Young
Mania Rating Scale, Bech-Rafaelsen Mania Scale, and Clinical Global Impression-Severity
(CGI-S). CBZ monotherapy produced significantly greater improvement on
manic measures at week 2 through endpoint and CGI-S of depression at endpoint
compared to placebo. CBZ monotherapy also yielded significantly higher
clinical response rates than placebo on bipolar depression (63.8% vs.
34.8%, p = 0.044) and mania (87.8% vs. 57.1%, p = 0.012).
Compared to CBZ monotherapy, adjunctive FEWP with CBZ resulted in significantly
better outcomes on the three measures of depression at week 4 and week
8 and significantly greater clinical response rate in depressed subjects
(84.8% vs. 63.8%, p = 0.032), but failed to produce significantly
greater improvement on manic measures and the response rate in manic subjects.
There was a lesser incidence of dizziness and fatigue in the combination
therapy compared to CBZ monotherapy. These results suggest that adjunctive
FEWP has additive beneficial effects in bipolar patients, particularly
for those in depressive phase.
Keywords: Herbal medicine; Carbamazepine; Bipolar disorders;
Bipolar depression; Mania; Clinical trial
Corresponding
author. Present address: Department of Psychiatry, Uniformed Services University
of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, United
States. Tel.: +1 301 295 1591; fax: +1 301 295 1042.
Journal
of Psychiatric Research
Volume 41, Issues 3-4, April-June 2007, Pages 360-369